Gene: MYCBP2

23077
Myc-bp2|PAM|Phr
MYC binding protein 2, E3 ubiquitin protein ligase
protein-coding
13q22.3
Ensembl:ENSG00000005810 MIM:610392 Vega:OTTHUMG00000017105 UniprotKB:O75592
NG_053031.1
PubMed
0   ANCO-SNPs
CD|OD|ND|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.560e-1 (AD)  9.775e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg03027750chr13:77899183MYCBP2Gene body6.213e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NBEA0.98
INPP4A0.972
AKT30.97
ZFYVE90.969
BHLHB90.967
SYNJ10.967
SLC35B40.967
LMTK20.966
PIK3CB0.965
FRMPD40.964

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HEY2-0.533
RAB13-0.526
MYL3-0.517
CSAG1-0.511
COPZ2-0.51
ROM1-0.504
YES1-0.484
RNF135-0.484
S100A16-0.472
CHST14-0.469

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of MYCBP2 mRNA"28973690
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MYCBP2 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of MYCBP2 mRNA19770486
D000638AmiodaroneAmiodarone affects the expression of MYCBP2 mRNA19483382
C006632arsenic trioxidearsenic trioxide results in increased expression of MYCBP2 mRNA20458559
D001280AtrazineAtrazine results in decreased expression of MYCBP2 mRNA25929836
D001553BenzbromaroneBenzbromarone affects the expression of MYCBP2 mRNA19483382
D001564Benzo(a)pyreneBenzo(a)pyrene affects the splicing of MYCBP2 exon26001963
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MYCBP2 mRNA20064835
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MYCBP2 mRNA22228805
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MYCBP2 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MYCBP2 mRNA"19150397
D004958EstradiolEstradiol results in decreased expression of MYCBP2 mRNA21185374
C543008bis(4-hydroxyphenyl)sulfone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MYCBP2 mRNA28628672
C006780bisphenol Abisphenol A affects the expression of MYCBP2 mRNA21786754
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MYCBP2 mRNA28628672
C006780bisphenol Abisphenol A results in increased expression of MYCBP2 mRNA25181051
D004390ChlorpyrifosChlorpyrifos results in decreased expression of MYCBP2 mRNA20691718
D002994ClofibrateClofibrate affects the expression of MYCBP2 mRNA19483382
D019327Copper SulfateCopper Sulfate results in increased expression of MYCBP2 mRNA19549813
D003375CoumestrolCoumestrol results in decreased expression of MYCBP2 mRNA19167446
C029892cupric chloridecupric chloride affects the expression of MYCBP2 mRNA19406218
C093628cyproconazolecyproconazole results in increased expression of MYCBP2 mRNA22045034
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of MYCBP2 mRNA23914054
D003907DexamethasoneDexamethasone results in increased expression of MYCBP2 mRNA25047013
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MYCBP2 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MYCBP2 mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of MYCBP2 mRNA21266533
D002945CisplatinCisplatin results in decreased expression of MYCBP2 mRNA27594783
D004041Dietary FatsDietary Fats results in increased expression of MYCBP2 mRNA19030233
D004041Dietary Fatsrimonabant inhibits the reaction [Dietary Fats results in increased expression of MYCBP2 mRNA]19030233
D0151279,10-Dimethyl-1,2-benzanthracene"9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MYCBP2 mRNA"22485181
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of MYCBP2 mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYCBP2 mRNA22079256
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of MYCBP2 mRNA17475347
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of MYCBP2 mRNA23550701
D005001EthionineEthionine affects the expression of MYCBP2 mRNA19483382
D005557FormaldehydeFormaldehyde results in increased expression of MYCBP2 mRNA14756816
C106014geduningedunin results in decreased expression of MYCBP2 mRNA17010675
D005839GentamicinsGentamicins results in increased expression of MYCBP2 mRNA22061828
C409722hexaconazolehexaconazole results in increased expression of MYCBP2 mRNA22045034
D017313FenretinideFenretinide results in decreased expression of MYCBP2 mRNA28973697
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of MYCBP2 mRNA17183730
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MYCBP2 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MYCBP2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MYCBP2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MYCBP2 mRNA28628672
C544151jinfukangjinfukang results in decreased expression of MYCBP2 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of MYCBP2 mRNA24796395
D007657Ketone BodiesKetone Bodies results in increased expression of MYCBP2 mRNA16807920
C008261lead acetatelead acetate affects the expression of MYCBP2 mRNA21147602
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of MYCBP2 mRNA26011545
D008942MitoxantroneMYCBP2 protein affects the susceptibility to Mitoxantrone16217747
C022838nickel chloridenickel chloride affects the expression of MYCBP2 mRNA22110744
D009853OmeprazoleOmeprazole affects the expression of MYCBP2 mRNA19483382
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of MYCBP2 mRNA25729387
D010634PhenobarbitalPhenobarbital affects the expression of MYCBP2 mRNA19159669
C006253pirinixic acidpirinixic acid results in decreased expression of MYCBP2 mRNA21318169
C006253pirinixic acidPPARA protein affects the reaction [pirinixic acid results in decreased expression of MYCBP2 mRNA]21318169
C006253pirinixic acidpirinixic acid affects the expression of MYCBP2 mRNA19483382
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYCBP2 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of MYCBP2 mRNA22079256
D011441PropylthiouracilPropylthiouracil affects the expression of MYCBP2 mRNA19483382
C089032rimonabantrimonabant inhibits the reaction [Dietary Fats results in increased expression of MYCBP2 mRNA]19030233
C009277sodium arsenatesodium arsenate results in increased expression of MYCBP2 mRNA21795629
D018038Sodium SeleniteSodium Selenite results in increased expression of MYCBP2 mRNA18175754
D012999SomanSoman results in decreased expression of MYCBP2 mRNA19281266
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MYCBP2 mRNA21570461
D013853ThioacetamideThioacetamide affects the expression of MYCBP2 mRNA19483382
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of MYCBP2 mRNA25729387
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of MYCBP2 mRNA24935251|2627250
C050414tripterinetripterine results in decreased expression of MYCBP2 mRNA17010675
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of MYCBP2 mRNA17183730
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MYCBP2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased methylation of MYCBP2 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of MYCBP2 mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of MYCBP2 mRNA17292431
D014635Valproic AcidValproic Acid results in increased expression of MYCBP2 mRNA22045034
D015054ZymosanZymosan results in increased expression of MYCBP2 mRNA14756816
D015054ZymosanZymosan results in increased expression of MYCBP2 protein14756816

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005085guanyl-nucleotide exchange factor activity-IDA26304119  
GO:0005515protein binding-IPI15161933  15324660  17353931  22357847  24136289  26496610  
GO:0008270zinc ion binding-IDA29643511  
GO:0008536Ran GTPase binding-IDA26304119  
GO:0061630ubiquitin protein ligase activity-IDA29643511  
GO ID GO Term Qualifier Evidence PubMed
GO:0006351transcription, DNA-templated-IEA-  
GO:0006355regulation of transcription, DNA-templated-IEA-  
GO:0016567protein ubiquitination-IDA29643511  
GO:0016567protein ubiquitination-IEA-  
GO:0021952central nervous system projection neuron axonogenesis-ISS-  
GO:0050905neuromuscular process-ISS-  
GO:1902667regulation of axon guidance-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA26304119  
GO:0016020membrane-HDA19946888  
GO:0043231intracellular membrane-bounded organelle-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal